In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents
Graphical abstract
Section snippets
Acknowledgments
The authors would like to thank Paul Shinn, Danielle VanLeer, and Jennifer Bennison for assistance with compound management. This work was supported by the Intramural Research Programs of the National Center for Advancing Translational Sciences and Public Health Service Grant AI101396 from the National Institute of Allergy and Infectious Diseases. T.Q.T. is a JSPS Research Fellow in Biomedical and Behavioral Research at the NIH.
References and notes (16)
Blood
(1959)- et al.
Mol. Biochem. Parasitol.
(2011) - et al.
Mol. Biochem. Parasitol.
(2013) - et al.
Ann. Oncol.
(2012) - et al.
J. Biomol. Screen.
(2006) - World Malaria Report 2014, World Health Organization (ISBN: 978 92 4 156483...
- et al.
Nat. Rev.
(2013) - et al.
Malaria J.
(2012)
Cited by (11)
Acid-Promoted Cascade Reaction of N-(4-Chloroquinolin-3-yl)carbamates with Amines: One-Pot Assembly of Imidazo[4,5-c]quinolin-2-ones
2018, European Journal of Organic ChemistrySynthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates
2016, Bioorganic and Medicinal ChemistryCitation Excerpt :Since the discovery of the natural product quinine, many compounds with a quinoline scaffold have displayed good antimalarial activity, leading to the development of effective antimalarial agents, including chloroquine, amodiaquine, piperaquine and mefloquine.6–8 Beside quinine analogs there are several other synthetic compounds were also reported.9–11 The existing antimalarial drugs are not adequate to combat malaria, primarily because of resistance developed by the parasite.
In silico-Based Structural Prediction, Molecular Docking and ADMET Analysis of Novel Imidazo-Quinoline Derivatives as Pf Purine Nucleoside Phosphorylase Inhibitors
2023, Current Signal Transduction TherapyA Quinquennial Review on Recent Advancements and Developments in Search of Anti-malarial Agents
2023, Current Topics in Medicinal ChemistryMalaria transmission blocking compounds: a patent review
2022, Expert Opinion on Therapeutic PatentsMalaria transmission-blocking drugs: Implications and future perspectives
2020, Future Medicinal Chemistry
- †
These authors contributed equally to this work.
- ‡
Current address: US Food & Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States.
- §
Current address: National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido 080-8555, Japan.
- ¶
Current address: aTyr Pharma Inc., 3545 John Hopkins Court, Suite #250, San Diego, CA 92121, United States.
- ‖
Current address: Microbiology and Immunology Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, United States.